The FDA approved Dupixent as the first treatment for allergic fungal rhinosinusitis in adults and children over six years old ...

People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...

The predictive variables assessed were age at EGPA diagnosis, baseline eosinophil count, history of chronic sinusitis prior to diagnosis, and glucocorticoid-treated asthma at diagnosis.

In today’s Healthy Minute, Dr. Kian Azimian will be discussing the differences between a sinus infection and seasonal ...

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...

Early symptoms that mimic common ear and sinus conditions often lead to delayed diagnosis.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients ...

Pharmacists have a seen a marked increase in patients turning to them for treatment for seven of the most common health ...

The Myers Cocktail refers to a combination of several vitamin and minerals that are typically administered intravenously or in some cases, intramuscularly, in an office setting.

Facial swelling can stem from allergies, infections, sinus issues or underlying disease.

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster ...